Prabhu Narayan 4
4 · REVIVA PHARMACEUTICALS HOLDINGS, INC. · Filed Mar 20, 2026
Research Summary
AI-generated summary of this filing
Reviva (RVPH) CFO Prabhu Narayan Receives Option Award
What Happened
Prabhu Narayan, Chief Financial Officer of Reviva Pharmaceuticals Holdings, Inc. (RVPH), received an option award on March 18, 2026 to acquire rights to 40,925 shares (reported as a derivative award; acquisition price $0). The exercise price will be equal to the company’s closing common stock price on the grant date per the issuer’s 2020 Equity Incentive Plan. This was a grant of options (compensation), not an immediate purchase or sale of shares.
Key Details
- Transaction date: March 18, 2026; Form 4 filed March 20, 2026.
- Award size: options covering 40,925 shares; reported value at grant: $0 (derivative award).
- Vesting: 12,789 shares vest immediately on the grant date; the remaining 28,136 vest in equal monthly installments from April 2026 through December 2028 (see footnote).
- Exercise price: set to the closing price of Reviva common stock on March 18, 2026 (per the 2020 Equity Incentive Plan).
- Shares owned after transaction: not specified in the filing.
- Filing timeliness: filed two days after the grant date (no late filing indicated).
Context
This is a compensation-related option grant (award), a common way companies pay executives; it does not involve an immediate cash outlay or sale. Because the exercise price is tied to the grant-date closing price, the options are essentially at- or near-market at grant; any future value depends on stock performance and vesting. Awards like this are not the same signal as an insider purchase (which can reflect a direct personal investment).
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-03-18+40,925→ 40,925 totalExercise: $1.87Exp: 2036-03-17→ Common Stock, par value $0.0001 per share (40,925 underlying)
Footnotes (1)
- [F1]This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.